With the advent of new targeted and cellular therapies, the treatment landscape for patients with chronic lymphocytic leukaemia (CLL) has considerably changed in the last few years. Current CLL management considers genetic aberrations, previous treatments, as well as disease relapse, in addition to the clinical stage. Oana Draghiciu and Inka Pawlitzky at CATO SMS describe contemporary CLL management, with a focus on current and emerging therapies in first-line disease and subsequent settings.